EICHORCondition: Myasthenia Gravis, Generalized · Sponsor: Dianthus Therapeutics
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Clinical Study Site | Phoenix, Arizona, United States | — |
| Clinical Study Site | Irvine, California, United States | — |
| Clinical Study Site | Stamford, Connecticut, United States | — |
| Clinical Study Site | Boca Raton, Florida, United States | — |
| Clinical Study Site | Bradenton, Florida, United States | — |
| Clinical Study Site | Maitland, Florida, United States | — |
| Clincal Study Site | Tampa, Florida, United States | — |
| Clinical Study Site | O'Fallon, Illinois, United States | — |
| Clinical Study Site | Kansas City, Kansas, United States | — |
| Clinical Study Site | Lexington, Kentucky, United States | — |
| Clinical Study Site | Boston, Massachusetts, United States | — |
| Clinical Study Site | East Lansing, Michigan, United States | — |
+ 44 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06282159